Islet Autoantibodies in Type 1 Diabetes

Islet autoantibodies are critical biomarkers for identifying and predicting the onset of Type 1 Diabetes (T1D). They target specific proteins in insulin-producing pancreatic beta cells, which are responsible for maintaining normal blood glucose levels. The most commonly detected islet autoantibodies include insulin autoantibodies (IAA), glutamic acid decarboxylase autoantibodies (GADA), and zinc transporter 8 autoantibodies (ZnT8A). These autoantibodies can appear months or even years before the clinical onset of T1D, making them valuable for early diagnosis and risk assessment. Detection of multiple islet autoantibodies is strongly associated with the development of T1D, providing a window of opportunity for preventive measures, clinical trials, and potential treatments aimed at preserving beta-cell function and delaying or preventing the full onset of the disease.